Asthma and COVID-19: do we finally have answers?

Eger, Katrien; Bel, Elisabeth H.

doi:10.1183/13993003.04451-2020

Cited by 38 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk of SARS-CoV-2 infection in patients with asthma is still a matter of discussion (111,112). Poorer outcomes in hospitalized patients with COVID-19 pneumonia and concomitant asthma were not related to the disease itself, but rather to older age and comorbidities, although corticosteroid therapy at high doses might be a confounding factor (113,114). Biologics may be protective both against the SARS-CoV-2 infection, by downregulating the angiotensin converting enzyme (ACE)2 (115) and the SARS-CoV-2-induced inflammatory response (116).…”

Section: Pulmonary Diseasesmentioning

confidence: 99%

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

et al. 2021

View full text Add to dashboard Cite

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

show abstract

Section: Pulmonary Diseasesmentioning

confidence: 99%

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The reported incidences of severe COVID-19 cases among asthma patients are not determined by patient-related factors alone. Moreover, local factors (testing policies or shielding advice, such as the case of the older patients or those with comorbidities like asthma better protected themselves) and the diagnostic methods to identify asthma and COVID-19 can play an important role [75].…”

Section: Severe Asthma and Covid-19mentioning

confidence: 99%

Asthma and COVID-19: a dangerous liaison?

Lombardi

Gani²,

Berti

et al. 2021

asthma res and pract

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking international public health crisis of our time. COVID-19 can cause a range of breathing problems, from mild to critical, with potential evolution to respiratory failure and acute respiratory distress syndrome. Elderly adults and those affected with chronic cardiovascular, metabolic, and respiratory conditions carry a higher risk of severe COVID-19. Given the global burden of asthma, there are well-founded concerns that the relationship between COVID-19 and asthma could represent a “dangerous liaison”.Here we aim to review the latest evidence on the links between asthma and COVID-19 and provide reasoned answers to current concerns, such as the risk of developing SARS-CoV-2 infection and/or severe COVID-19 stratified by asthmatic patients, the contribution of type-2 vs. non-type-2 asthma and asthma-COPD overlap to the risk of COVID-19 development. We also address the potential role of both standard anti-inflammatory asthma therapies and new biological agents for severe asthma, such as mepolizumab, reslizumab, and benralizumab, on the susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes.

show abstract

“…There has been a higher frequency of asthma among COVID-19 patients compared to the general population (2.9 vs. 1.6-2.2%), as well as a higher frequency of COVID-19 infection amongst asthma patients compared to the general population (1.41 vs. 0.86%). In addition, the possibility of contracting COVID-19 is higher in asthma patients than in the general population [10]. On the other hand, numerous patients with asthma are infected with the SARS-CoV-2 virus.…”

Section: Fig (1)mentioning

confidence: 99%

Post-Coronavirus Era: Should We Expect a Surge in Allergic Diseases and Asthma?

Nasab¹,

Athari²

2021

TOPHJ

View full text Add to dashboard Cite

Some infectious agents by priming the immune system promote protection against allergy and asthma. During infections, Th1 immune responses are dominant, while in allergic conditions, Th2 responses are more pronounced. Th1 immune response protects the body against infections, and Th2 response leads to allergy and asthma. For maintaining health, the balance between Th1 and Th2 responses is necessary. The COVID-19 infection augments Th1 and also eosinophilic responses. On the other hand, the main protocols to control the COVID-19 pandemic require adherence to health standards, maintaining personal hygiene, frequent disinfecting of hands, using face masks, etc. In the post-COVID-19 era, this sterile condition may relinquish, and the Th1/Th2 immune imbalance may lead to an increase in the incidence of allergy and asthma. Therefore, focus on the COVID-19 infection should not deter us from foreseeing a surge in asthma and other post-coronavirus problems.

show abstract

Asthma and COVID-19: do we finally have answers?

Cited by 38 publications

References 28 publications

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

Asthma and COVID-19: a dangerous liaison?

Post-Coronavirus Era: Should We Expect a Surge in Allergic Diseases and Asthma?

Contact Info

Product

Resources

About